Researchers have long suspected that microorganisms play a role in the development of giant cell arteritis; data showing that patients with the disease have a distinct microbiome are the first step toward determining that function.
Findings from a mouse model provide support for a new drug class that acts on gut microbes to reduce platelet responsiveness and thrombosis risk without promoting bleeding or antibiotic resistance.
Antibiotics and a high-fat, high-sugar diet significantly and persistently inhibited microbial oxalate metabolism by gut microbiota in a mouse model. Important implications for kidney stone development and prevention.
Diet modifications aimed at restoring and sustaining beneficial gut bacteria can improve clinical results in patients with chronic kidney disease, says Cleveland Clinic nephrologist Priya Kalahasti, MD. Reducing protein, increasing vegetables, adding probiotics and periodically fasting to rest the gut has improved patients’ lab test values such as serum creatinine and glomerular filtration rate.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The microbiome — and using it to prevent, diagnose and treat disease — will be the No. 1 most influential medical innovation in 2017, predict experts at Cleveland Clinic.
Biologic Therapies VII Summit in April 2-17 will help clinicians understand and harness the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.
Investigators are analyzing microbiomes in several solid tumors. If microbiome elements are involved in carcinogenesis, they could serve as biomarkers for progression and prognosis, as well as therapeutic targets.